Expert opinions · patient guide

Lung cancer: what an expert review can clarify

A lung cancer expert review is a records-based opinion from a specialist or a small multidisciplinary team. It can clarify whether the diagnosis and staging are complete, whether the pathology and molecular results support the proposed treatment, and which options are worth discussing. It cannot confirm hospital acceptance, guarantee an outcome, or replace the treating team's own assessment in China.

Go to the practical guidance ↓
AI illustration: A doctor in a white coat consulting with a male patient in an office setting.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

What a records-based review can and cannot settle

An expert review works from documents: imaging, pathology reports and slides, molecular and genomic results, operation notes, treatment records and the current clinical question. The reviewer reads that file and gives an opinion. This is different from an in-person consultation, where the clinician examines the patient, and different again from a hospital's own admission assessment.

What the review can do is identify gaps and inconsistencies. It can point out that a staging scan is missing, that a pathology report does not state the histologic subtype clearly, or that a molecular result was reported on a sample that may not be adequate. It can explain how the findings map onto recognised staging and treatment frameworks, and set out the options that a tumour board would reasonably discuss.

What it cannot do is confirm that a particular hospital will accept the patient, that a named treatment is available on a given date, or that a proposed plan will work. Those are decisions for the treating hospital and licensed clinicians after they assess the patient and the full record. A review narrows the questions; it does not close them.

The diagnosis and staging questions a review often exposes

Lung cancer planning depends on two things being right: what the cancer is, and how far it has spread. A review usually starts there. The pathology report should state the histologic type, because non-small cell and small cell lung cancer follow different treatment paths, and within non-small cell disease the distinction between adenocarcinoma, squamous cell carcinoma and other subtypes matters.

Staging is the second axis. Staging for lung cancer is conventionally described using the TNM system, which records tumour size and local invasion (T), nodal involvement (N) and distant spread (M), and groups these into stages. The American Joint Committee on Cancer and the Union for International Cancer Control publish the staging manuals that clinicians use; the current edition is the eighth. A review can check whether the imaging and any biopsy results have been assembled into a coherent stage, and whether the stage recorded in the notes matches the evidence.

This is where reviews often add value. A patient may arrive with a stage written on a discharge summary but no clear record of which scan established it, or with a staging PET-CT reported before a confirmatory biopsy. The reviewer can say what is established, what is assumed, and what the treating team would need to confirm before committing to a plan. The review does not perform the staging itself; it clarifies what the existing records support.

Pathology, molecular testing and why the sample matters

For non-small cell lung cancer, treatment selection increasingly depends on molecular features of the tumour. Guidelines from the National Comprehensive Cancer Network and the European Society for Medical Oncology recommend testing for driver alterations such as EGFR mutations, ALK and ROS1 rearrangements, and in many settings BRAF, KRAS, MET, RET, NTRK and others, along with PD-L1 expression, which informs immunotherapy decisions. The exact panel a laboratory offers varies, and the treating team decides which tests are appropriate for a given patient.

A review can clarify whether the testing already done is adequate for the decision at hand. A common issue is sample quantity: a small biopsy or cytology specimen may be enough for diagnosis but not for a broad molecular panel. The reviewer can note that the reported result covers some markers but not others, and that the treating team may need to discuss further testing, including whether a new tissue sample is feasible. That is a question for the treating clinicians, not a decision the review makes.

Pathology review by a second specialist is a related but distinct step. Re-reading slides can confirm or refine the histologic classification, which matters when the original report is ambiguous. Whether a second pathology opinion is worthwhile in a particular case is something to ask the receiving hospital, because it depends on the material available and the clinical question.

Treatment options: what the review can frame, not decide

Once diagnosis, stage and molecular profile are clear, the treatment discussion usually involves surgery, radiotherapy, systemic therapy (chemotherapy, targeted therapy, immunotherapy) or some combination. Which applies depends on stage, histology, molecular results, lung function, other medical conditions and the patient's own priorities. A multidisciplinary tumour board — typically thoracic surgery, medical oncology, radiation oncology, radiology and pathology — is the usual forum for that discussion in complex cases.

A records-based review can explain how the case sits against published frameworks and what a tumour board would likely consider. It can flag that, for example, a patient with early-stage disease and adequate lung function might be assessed for surgery, while a patient with widespread disease would usually be assessed for systemic therapy first. It can also identify the questions the patient should put to the treating team: whether surgery is technically feasible, what lung function testing would be needed, whether the molecular result opens a targeted option, and what the alternatives are if the first plan is not suitable.

What the review should not do is present a plan as settled. Suitability for surgery, radiotherapy or a particular drug is a clinical judgement made after examination, functional testing and review of the full record. The review's job is to make that conversation sharper, not to pre-empt it.

Preparing records for a review in China

The quality of a review depends on the file. A useful submission is organised by question rather than by date alone. Start with a short summary: the diagnosis as currently understood, the stage as currently recorded, what treatment has been given, and the specific question the patient wants answered. Then attach the supporting documents.

Imaging is often the limiting factor. Reports alone may not be enough if the reviewer needs to see the scans; ask the receiving service whether DICOM images on disc or a secure upload are required, and in what format. Pathology slides or blocks may be requested for a second opinion; whether they can be shipped and how is a question for the receiving hospital and the laboratory that holds them. Molecular reports should include the test method and the sample type, not just the result.

Language matters. Reports in a language other than English or Chinese may need translation, and the reviewer needs to know which documents are originals and which are summaries. It is reasonable to ask, before submitting, what the service needs and what it will not be able to assess from the records alone. A brief initial enquiry is the right place to ask those questions; it does not commit the patient to a paid consultation.

  • A one-page summary stating the diagnosis, stage, prior treatment and the specific question
  • Imaging reports plus, where requested, the images themselves in the format the service specifies
  • Pathology reports with histologic subtype, and slides or blocks if a second opinion is being considered
  • Molecular and genomic reports with test method and sample type
  • Operation notes, discharge summaries and current medication list
  • Translations where needed, with a note on which documents are originals

Where ChinaSpecialistCare fits, and the limits of that role

ChinaSpecialistCare provides information and non-clinical coordination for international patients considering care in China. The team can check whether the available diagnosis, records and main question are clear enough for a review, identify missing information, and suggest a relevant next step. That initial case review is free and is not a diagnosis or a promise of acceptance.

For a records-based opinion, an optional proxy consultation is available: our doctor takes the patient's records to a relevant hospital specialist for an opinion while the patient remains at home. A proxy consultation is optional and is not a prerequisite for every appointment or operation. For complex or cross-specialty cases, a multidisciplinary review involving two or three relevant specialties may be arranged, with scope and fee agreed first. Specialist matching and appointment coordination is a separate service; hospital consultation fees are separate.

These services do not decide suitability, treatment or hospital acceptance. Those rest with the treating hospital and licensed clinicians. A review can make the questions clearer and the records more complete; it cannot establish that a particular treatment is available, appropriate or funded for an individual patient.

A practical next step is to send a short summary through the enquiry form, email or WhatsApp, describing the diagnosis as currently understood and the question you want answered. The team will explain what records to share after first contact. Do not send passport numbers, card details or a complete medical archive in that first message.

Related treatment reference

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. Overview | Lung cancer: diagnosis and management | Guidance | NICE

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.